← Back

Wellumio

Wellington, New Zealand

seed$9.8M raisedFreshly fundedMedtechAI & MLDiagnostics

Total Raised

$9.8M

Stage

seed

Location

Wellington, New Zealand

Founded

2022

Team size

11-50

Links

About Wellumio

Wellumio is developing Axana, a portable brain imaging system for point-of-care stroke detection.

What sets it apart

Its portable MRI-based system uses proprietary PGFM technology to enable bedside stroke imaging without traditional MRI infrastructure such as helium cooling or RF-shielded rooms.

Sectors

MedtechAI & MLDiagnostics

Business

Modelhardware

CustomerHospitals, emergency departments, stroke care teams, and healthcare providers needing rapid brain imaging at the point of care

Notable

  • Co-founded in early 2022
  • Enrolled the first patient in an Australian clinical trial for Axana
  • Raised an oversubscribed $9.75M pre-Series A round
  • Secured a U.S. patent for its imaging technology

Funding rounds

seed$9.8M

29 Jul 2026

Led by Nuance Connected Capital

With Icehouse Ventures, Aspire Seed Fund, Pacific Channel, Booster, Cure Kids Ventures, Flying Kiwi, Enterprise Angels, Snowball Effect, Bioshore Ventures, Jumpspace Ventures

Source ↗

Explore the market

FAQ

What does Wellumio do?

Wellumio is developing Axana, a portable brain imaging system for point-of-care stroke detection.

Where is Wellumio based?

Wellumio is based in Wellington, New Zealand, founded in 2022.

How much has Wellumio raised?

Wellumio has raised $9.8M in tracked funding and is currently at the seed stage.

Who has invested in Wellumio?

Investors in Wellumio include Nuance Connected Capital, Icehouse Ventures, NZGCP Aspire Seed Fund, Pacific Channel, Booster, Cure Kids Ventures, Enterprise Angels and Flying Kiwi.